JOMMI, C.; CAVAZZA, M. Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. Global and Regional Health Technology Assessment, [S. l.], v. 6, n. 1, 2019. DOI: 10.33393/grhta.2019.460. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/460. Acesso em: 28 mar. 2024.